Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes

Abstract

The invention concerns compounds of formula CH 3 —R 1 —(CH 2 ) 2 —R 2 wherein: R 1 is selected among a tertiary alcohol; a 1,2-diol; a halohydrine; an epoxide; an alkene; an aldehyde or an α-hydroxyaldehyde; and R 2 is selected among a methylenediphosphonate; a difluoromethylenediphosphonate; or a monofluoromethylenediphosphonate. The invention also concerns the uses of said compounds as selective inhibitors of Tγ9δ2 lymphocytes, and their uses, in particular for therapeutic purposes.

1 . A therapeutic or diagnostic composition, comprising an excipient or pharmaceutical additive and a compound having the following formula:  
       H 3 C—R 1 —(CH 2 ) 2 —R 2   (I)  wherein R 1  is selected from the group consisting of                          wherein R 2  is selected from the group consisting of                          and wherein Cat+ represents one or more organic or mineral cations, comprising the proton, identical or different, in the same compound, excepting 3-methyl-3-butene-1-yl-difluoromethylenediphosphonate, and 3-methyl-3-butene-1-yl-methylenediphosphonate.    
     
     
         2 . The composition according to  claim 1 , wherein said excipient or pharmaceutical additive is a vaccine adjuvant.  
     
     
         3 . The composition according to  claim 1 , wherein said composition can be safely administered to a primate.  
     
     
         4 . A method for selectively inhibiting Tγ9δ2 lymphocytes, comprising: 
 contacting said Tγ9δ2 lymphocytes with an effective amount of the composition according to  claim 1 .  
 
     
     
         5 . A method for treating a patient that suffer from a pathology that activates Tγ9δ2 lymphocytes, comprising: 
 administering to said patient in need thereof an effective amount of the composition according to  claim 1 .  
 
     
     
         6 . A method for treating a pathology leading to an activation of Tγ9δ2 lymphocytes in a primate, comprising: 
 administering to said primate in need thereof an effective amount of the composition according to  claim 1 .  
 
     
     
         7 . A method for treating parasitosis in a primate, comprising: 
 administering to said primate in need thereof an effective amount of the composition according to  claim 1 .    
     
     
         8 . The method according to  claim 6 , wherein said parasitosis is selected from the group consisting of malaria, visceral leishmaniosis, toxoplasmosis.  
     
     
         9 . A method for treating an autoimmune malady in a primate, comprising: 
 administering to said primate in need thereof an effective amount of the composition according to  claim 1 .    
     
     
         10 . The method according to  claim 8 , wherein said malady is behcet malady.  
     
     
         11 . A method for selectively inhibiting Tγ9δ2 lymphocytes in an extracorporeal medium, comprising: 
 contacting said Tγ9δ2 lymphocytes in said extracorporeal medium with an effective amount of the composition according to  claim 1 .  
 
     
     
         12 . A method for inhibiting polyclonal proliferation of Tγ9δ2 lymphocytes, comprising: 
 contacting said Tγ9δ2 lymphocytes with an effective amount of the composition according to  claim 1.